Search
Contact Us
LinkedIn
Twitter
About Stoke
Overview
Leadership
Founders
Corporate Responsibility
Scientific Platform
Overview
TANGO
Publications
Disease Areas
Overview
Dravet Syndrome
ADOA
SYNGAP1
Pipeline
Patients & Families
Overview
Clinical Studies
Expanded Access Policy
Educational Resources
Careers & Culture
Overview
Job Opportunities
Diversity, Inclusion & Belonging
Investors & News
Overview
Media Room
Press Releases
Events & Presentations
Financials & SEC Filings
Stock Information
Analyst Coverage
Governance
Settlement Information
Menu
Search
About Stoke
Overview
Leadership
Founders
Corporate Responsibility
Scientific Platform
Overview
TANGO
Publications
Disease Areas
Overview
Dravet Syndrome
ADOA
SYNGAP1
Pipeline
Patients & Families
Overview
Clinical Studies
Expanded Access Policy
Educational Resources
Careers & Culture
Overview
Job Opportunities
Diversity, Inclusion & Belonging
Investors & News
Overview
Media Room
Press Releases
Events & Presentations
Financials & SEC Filings
Stock Information
Analyst Coverage
Governance
Settlement Information
Contact Us
Home
Scientific Platform
Publications
Dravet Syndrome Presentations
Zorevunersen (STK-001) demonstrates potential for disease modification, including reductions in seizures and improvements in cognition and behavior in children and adolescents with Dravet syndrome
Topic:
Dravet Syndrome Presentations
Zorevunersen (STK-001) demonstrates potential for disease modification, including reductions in seizures and improvements in cognition and behavior in children and adolescents with Dravet syndrome
AES 2024
December 6, 2024
View Poster
Patients with Dravet syndrome in open-label extension studies of zorevunersen (STK-001) have durable reductions in seizure frequency and ongoing improvements in cognition and behavior
AES 2024
December 6, 2024
View Poster
Small changes on the Vineland-3 are meaningful to caregivers of patients with Dravet syndrome
AES 2024
December 6, 2024
View Poster
Spectral EEG analysis demonstrates decreased slow-wave activity in patients with Dravet syndrome after treatment with zorevunersen (STK-001), an antisense oligonucleotide
AES 2024
December 6, 2024
View Poster
24-Month Analysis of BUTTERFLY A Prospective, Observational Study to Investigate Seizures and Comorbidities in Children and Adolescents with Dravet Syndrome
EEC 2024
September 10, 2024
View Poster
